DapaN introduces the world’s first SGLT2 inhibitor nano-eye-drop, encapsulating dapagliflozin into stable polymer/cyclodextrin micelles (100–170 nm). The formulation overcomes tear dilution and corneal barriers, prolongs ocular retention, and delivers the drug directly to the lens—a pharmacological breakthrough beyond surgery. Mechanism & Efficacy: By modulating the SGLT2–AKR1B1–RAGE–EMT axis and attenuating oxidative stress, DapaN prevents lens epithelial cell damage and fibrotic transition. In